Françoise Martin-Nizard

Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin

This study attempted to determine if low density lipoproteins (LDL) induce the production of endothelins (ET) by human macrophages. Non‐protected LDL from macrophage induced oxidation (n‐LDL), copper‐oxidized LDL (Ox‐LDL), acetylated‐LDL (Ac‐LDL), butylated hydroxytoluene‐LDL (BHT‐LDL), BHT‐Ac‐LDL, polyinosinic acid (PiA, 1.5μg/ml), phorbol myristate acetate (PMA; 0.5 μM) and BHT alone (20 μM) were studied. The different compounds had the following potency to stimulate the ET secretion: PMA>Ox‐LDL>Ac‐LDL>n‐LDL>BHT‐LDL>PiA>PiA+Ac‐LDL>BHT. In conclusion, mod stimulated ET secretion by human macrophages.

Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells.

Endothelin is a potent vasoconstrictor peptide isolated from endothelial cells and it induces smooth muscle cell proliferation. Endothelin-1 secretion is increased in atheroma and induces deleterious effects such as vasospasm and atherosclerosis. Oxidized low-density lipoproteins (LDLs) induce atherosclerosis in the vascular wall, as well as endothelin-1 secretion in endothelial cells and are activators of both peroxisome proliferator–activated receptor-&agr; (PPAR-&agr;) and PPAR-&ggr;. PPAR-&agr; (fibric acids) and PPAR-&ggr; (glitazones) activators are used to treat dyslipoproteinemias and type 2 diabetes, respectively. Furthermore, these drugs induce numerous pleiotropic effects, such as inhibiting thrombin-induced endothelin-1 secretion in endothelial cells. This study shows that both PPAR-&agr; (Wy 14643) and PPAR-&ggr; activation (rosiglitazone) partially inhibit oxidized LDL–induced protein kinase C activity and endothelin-1 secretion in endothelial cells at the transcriptional levels and suggests that synthetic PPAR activators are stronger PPAR activators than oxidized LDL. This study also suggests that fibrate and glitazone treatments should have beneficial effects on the vascular wall by reducing endothelin-1 secretion and the resulting vasospasm and atherosclerosis.

The PPARα activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy

It has been reported that high intramyocardial peroxisome proliferator-activated receptor α (PPARα) stimulation or overexpression altered cardiac contractile function in mouse models of cardiac hypertrophy and heart failure. Nevertheless, it has never been demonstrated that clinically relevant doses of drugs stimulating PPARα activity such as fenofibrate increase the risk to develop heart failure in humans. To determine if fenofibrate accelerates the development of heart failure in large mammals, we have tested its effects on the progression of left ventricular dysfunction in pacing-induced heart failure in pigs. Fenofibrate treatment blunted reduction in left ventricular ejection fraction, reduced cardiac hypertrophy, and attenuated clinical signs of heart failure. Fenofibrate impeded the increase in atrial natriuretic peptide, brain natriuretic peptide, and endothelin-1 plasma levels. The expression of PPARα, fatty acyl-CoA-oxidase, and carnitine palmitoyltransferase-Iβ was reduced at mRNA levels in the left ventricle from untreated heart failure pigs but maintained near normal values with fenofibrate. Fenofibrate prevented heart failure-induced overexpression of TNFα mRNA and enhanced catalase activity in left ventricle compared to placebo. These data suggest that a clinically relevant dose of fenofibrate does not accelerate but slows down heart failure development in the model of pacing-induced heart failure in large mammals.

Vasorelaxant and anti-platelet aggregation effects of aqueous Ocimum basilicum extract

AIM OF THE STUDY In this work the endothelium-dependant vasorelaxant and anti-platelet aggregation activities of an aqueous extract from Ocimum basilicum were studied. MATERIALS AND METHODS The vasorelaxant effect was undertaken in thoracic aorta from three experimental groups of rats: one of them (NCG) fed with standard diet, the second (HCG) with hypercholesterolemic diet (HCD) and the third (BTG) with hypercholesterolemic diet together with an intragastric administration of Ocimum basilicum extract at a dose of 0.5 g/kg body weight for a period of 10 weeks. The in vitro anti-platelet aggregation of Ocimum basilicum extract was studied using thrombin (0.5 U/ml) and ADP (5 microM) as agonists. RESULTS The results show that the HCD statistically decreases vascular relaxation in HCG compared to NCG (p<0.001) and increases the vascular responses to phenylephrine (p<0.02). Ocimum basilicum extract exerts a significant vasorelaxant effect at 10(-5) M (p<0.01) and 10(-4) M carbachol (p=0.001). The plant extract also tends to suppress the elevated contractions induced by HCD (p=0.05). The extract inhibits ADP-induced platelet aggregation by 13%, 28.2%, 30.5%, 44.7% and 53% at a dose of 1, 2, 3, 4 and 5 g/l, respectively. Thrombin-induced platelet activation was also reduced by 15%, 23%, 40%, 38.4%, and 42% at the same doses of extract described above. CONCLUSION The use of Ocimum basilicum as medicinal plant could be beneficial for cardiovascular system.

Paullinia pinnata extracts rich in polyphenols promote vascular relaxation via endothelium-dependent mechanisms

Paullinia pinnata L. (Sapindaceae) is an African tropical plant whose roots and leaves are used in traditional medicine for many purposes, especially for erectile dysfunction, but its action mechanism is unknown. P. pinnata root and leaf methanolic extracts are rich in phenolic compounds. This study shows that both extracts are highly antioxidative and induce a slight transcriptional activity of peroxisome proliferator activated receptor-α. They also increased and decreased endothelial nitric oxide synthase and endothelin-1 mRNA levels in bovine aortic endothelial cells, respectively. In this study P. pinnata methanolic extracts in cumulative doses elicited in a dose-dependent manner the relaxation of phenylephrine precontracted isolated rat aortic rings. NG-nitro-L-arginine methyl ester significantly attenuated the capacity of both extracts to induce arterial relaxation, indicating that this arterial relaxation was mediated by endothelial nitric oxide release. It could be suggested that the arterial relaxation induced by both extracts could be mainly linked to their capacities to inhibit nitric oxide oxidation through their antioxidant properties.

Alpha-Tocopherol But Not Beta-Tocopherol Inhibits Thrombin-Induced PKC Activation and Endothelin Secretion in Endothelial Cells

Introduction Production of endothelin by endothelial cells depends on protein-kinase C (PKC) stimulation which has been reported to be inhibited by alpha-tocopherol (α-Toch) but not by beta-tocopherol (β-Toch). The goal of this study was to determine whether α-Toch and β-Toch inhibit endothelin secretion by endothelial cells. Methods and results In a first set of experiments, cultured bovine aortic endothelial cells (BAEC) were incubated for 48 h with 100 μmol/l α-Toch or vehicle (0.1% ethanol), then cells were stimulated for 4 h or 20 h with thrombin. After stimulating bovine aortic endothelial cells with thrombin for 4 h, α-Toch inhibited PKC activity by 63% and endothelin secretion by 44%, whereas after 20 h of incubation with thrombin, α-Toch decreased the peptide secretion by 51%. In a second set of experiments, BAEC were incubated with increased concentrations (from 0 to 100 μmol/l) of α-Toch or β-Toch, PKC activity and endothelin secretion were measured after thrombin stimulation as previously reported. In these experiments, α-Toch strongly inhibited thrombin-induced PKC activity and endothelin secretion in a dose-dependent manner, whereas β-Toch was more than 10-fold less active than α-Toch in inhibiting these stimulations. Tocopherols (α-Toch + β-Toch) produced a proportional correlation on both PKC stimulation and endothelin secretion by inhibiting the effect of thrombin. Conclusion These data suggest that α-Toch strongly inhibits thrombin-induced endothelin secretion in vitro at least partly through PKC inhibition.

A High Concentration of Melatonin Inhibits In Vitro Ldl Peroxidation But Not Oxidized Ldl Toxicity Toward Cultured Endothelial Cells

The pineal hormone, melatonin, was recently found to be a potent free scavenger for hydroxyl and peroxyl radicals. Melatonin also inhibits neuronal and thymocyte damage due to oxidative stress. Atherosclerosis development is mediated by low-density lipoprotein (LDL) oxidation and the endocytosis of oxidized LDL by resident macrophages in the subendothelial vascular wall. Furthermore, the cytotoxic effect of oxidized LDL increases atherogenicity. The goal of this study was to compare the antioxidant activities of melatonin and vitamin E against in vitro LDL oxidation and their cytoprotective actions against oxidized LDL-induced endothelial cell toxicity. An attempt at loading LDL with melatonin by incubating human plasma with an ethanolic melatonin solution gave only low protection against Cu2+-induced LDL oxidation in comparison with vitamin E and gave no detectable incorporation of melatonin into LDL, measured by high-performance liquid chromatography (HPLC) coupled to UV detection. High concentrations of melatonin (10-100 microM) added to the oxidative medium induced a clear inhibition of Cu2+-induced LDL oxidation, characterized as an increase in the lag-phase duration of conjugated diene formation and decreases in the maximal rate of the propagation phase and in the maximal amount of conjugated diene formation. Determination of the median efficacious dose (ED50) of melatonin and vitamin E by their ability to increase lag-phase duration showed that melatonin was less active than vitamin E (ED50, 79 vs. 10 microM, respectively). Melatonin was also less active than vitamin E in limiting the formation of thiobarbituric acid-reactive substances (TBARS) and LDL fluorescence intensity increase in the medium during Cu2+-induced LDL oxidation. Cu2+-induced LDL oxidation in the presence of 100 microM melatonin produced oxidized LDLs that were less recognizable for the scavenger receptors of J774 macrophages than were untreated LDLs. Vitamin E, 10 microM, was more active than 100 microM melatonin in inhibiting LDL oxidation and the resulting lipoprotein alterations leading to binding internalization and degradation by the J774 macrophages. Vitamin E, 100 microM, inhibited the pursuit of the oxidation of oxidized LDL mediated by bovine aortic endothelial cells (BAECs) in a culture medium containing Cu2+, whereas 100 microM melatonin had no antioxidant effect. Melatonin, 100 microM, as well as 100 microM vitamin E inhibited intracellular TBARS formation during the incubation of BAECs with highly oxidized LDL but had no influence on the increase in glutathione (GSH) concentration during this lengthy exposure (16 h) of BAECs to highly oxidized LDL. During this period, the same dose of vitamin E but not of melatonin tended to limit the decrease in adenosine triphosphate (ATP) concentration. Vitamin E, 100 microM, did not significantly reduce cellular lactate dehydrogenase (LDH) release in the culture medium during the incubation of oxidized LDL with BAECs, whereas 100 microM melatonin dramatically increased this release. These data show that melatonin is less active than vitamin E in inhibiting in vitro LDL oxidation and does not inhibit the cytotoxicity of oxidized LDL toward cultured endothelial cells. The concentrations necessary to inhibit LDL oxidation are far beyond those found in human plasma (100 microM vs. 100 pM). Therefore our results indicate that the pineal hormone melatonin per se appears to have little antiatherogenic property in the in vitro oxidation of LDL and the cytoprotective action against the toxicity of oxidized LDL. Nevertheless, in vivo LDL oxidation takes place in the subendothelium of the artery wall, and nothing is known about the concentration of melatonin or its catabolites in this environment.

Analysis of phospholipid transfer during hdl binding to platelets using a fluorescent analog of phosphatidylcholine

Electron microscopic examination of the interaction of gold labelled HDL with platelets indicates that the internalized lipoprotein becomes closely associated with surface connected canaliculae and endocytic vacuoles. At the same time granule centralization occurs. Using fluorescent derivatives of naturally occurring lipids we have further investigated lipid exchange between HDL and platelets. Analogs of phosphatidylcholine containing fluorescent fatty acids are rapidly transferred from the lipoproteins to the cells and remain at the plasma membrane as long as they are kept at 4 degrees C. However when the platelets are warmed to 37 degrees C, a rapid degradation of the fluorescent lipids occurs, generating fluorescent diacylglycerol as a consequence of the activation of platelet enzymes.

Interactions of high-density lipoprotein 3 with brain capillary endothelial cells.

High-density lipoprotein 3 (HDL3) binds to capillary endothelial cells when their lumen surfaces are exposed to 125I-HDL3 by post-mortem perfusion of whole brain. Kinetic studies of binding of HDL3 to isolated membranes show that HDL3 binds only to endothelial membranes with high affinity (Kd = 7 micrograms/ml). Trypsin treatment of membranes abolishes HDL3 binding. High-affinity binding sites for HDL3 were recovered when endothelial cells from bovine brain capillaries were maintained in culture (Kd = 13 micrograms/ml HDL3 protein). The characteristics of the binding were preserved up to the 6th passage. Competition experiments using isolated luminal membranes or cultured endothelial cells indicate that only HDL3 and not LDL or methylated LDL, are able to compete binding of 125I-HDL3. Furthermore, the inhibition of 125I-HDL3 binding by lipoprotein A-I and lipoprotein A-I:A-II strongly suggests that apolipoprotein A-I is implicated in the formation of HDL3-receptor complexes. The binding is increased by loading cells with free cholesterol or LDL cholesterol. In addition, surface-bound 125I-HDL3 remains sensitive to mild trypsin treatment after subsequent incubation of BBCE at 37 degrees C. HDL3 bound to the cell surface is not endocytosed, but rather rapidly released into the medium after binding (t1/2 = 5 min).

Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferator–Activated Receptor α–Dependent and Independent Mechanisms in Human Endothelial Cells

Objective—Dyslipidemia contributes to endothelial dysfunction in type 2 diabetes mellitus. Fenofibrate (FF), a ligand of the peroxisome proliferator–activated receptor-&agr; (PPAR&agr;), has beneficial effects on microvascular complications. FF may act on the endothelium by regulating vasoactive factors, including endothelin-1 (ET-1). In vitro, FF decreases ET-1 expression in human microvascular endothelial cells. We investigated the molecular mechanisms involved in the effect of FF treatment on plasma levels of ET-1 in type 2 diabetes mellitus patients. Methods and Results—FF impaired the capacity of transforming growth factor-&bgr; to induce ET-1 gene expression. PPAR&agr; activation by FF increased expression of the transcriptional repressor Krüppel-like factor 11 and its binding to the ET-1 gene promoter. Knockdown of Krüppel-like factor 11 expression potentiated basal and transforming growth factor-&bgr;–stimulated ET-1 expression, suggesting that Krüppel-like factor 11 downregulates ET-1 expression. FF, in a PPAR&agr;-independent manner, and insulin enhanced glycogen synthase kinase-3&bgr; phosphorylation thus reducing glycogen synthase kinase-3 activity that contributes to the FF-mediated reduction of ET-1 gene expression. In type 2 diabetes mellitus, improvement of flow-mediated dilatation of the brachial artery by FF was associated with a decrease in plasma ET-1. Conclusion—FF decreases ET-1 expression by a PPAR&agr;-dependent mechanism, via transcriptional induction of the Krüppel-like factor 11 repressor and by PPAR&agr;-independent actions via inhibition of glycogen synthase kinase-3 activity.